Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial.

ABSTRACT:

Purpose

This phase 1 trial evaluated the safety, preliminary efficacy, and pharmacokinetics of surufatinib, a small molecular tyrosine kinase inhibitor, combined with toripalimab, a programmed cell death protein-1 antibody, in patients with advanced solid tumors.

Methods

This is an open-label, dose-escalation and expansion study in patients with solid tumors who had failed standard therapies or had no effective treatment. In the dose-escalation stage, patients were treated with surufatinib, at dose levels of 200, 250, or 300 mg once daily (QD) in combination with toripalimab 240 mg, every 3 weeks (Q3W), to estimate maximum tolerated dose. Additional patients were enrolled in the dose expansion stage to further assess the efficacy, safety, and pharmacokinetics profile. Recomm

SUBMITTER: Cao Y 

PROVIDER: S-EPMC9931771 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature